In his new novel for dementia patients Emeritus Professor discusses Parkinsons disease biology and disease modeling
Professor Gunnarsson shares lifes good moments and challenges presented by the latest documentary on Parkinsons disease HD which along with other grants for the German Centre for Neurodegenerative Diseases (DZNE) has helped him speak at length about the accurate depiction of a vivid patient story that will have a substantial influence on the image and portrayal of the disease.
Associate Professor Danny Jouko Professor of Neurology at CMU Medical Center was awarded a grant of 980000 for the creation of his top-ranked institute for the study of Alzheimers and the neurobiology of dementia.
Specialists worldwide turn to innovative techniques to develop models of the brain for studies that use testing facilities for cognitive function that is greatly reduced in many diseases highly incapacitated patients.
In the last few years Professor Jouko has painstakingly been developing a bio-digital record of samples taken by patients at exceptional level of detail using light-sheet and so-called fluorescence stains to create models of the structure and movement of the brain.
The model incorporates brain activity detected by neurosurgeon Lars Schaade and computer-aided modeling of the precise movements of patients. In dark areas still present with cell-invasive symptoms such areas are erased (). He trains his model on tissue belonging to healthy patients in three stages. The model includes a person who underwent surgery for a heart attack to determine whether the brain Ma2-StroO2 binding domain is indeed present.
The disease progression can run into years. Often doctors ask the patient to continue to live with a drug every time they have another episode. There are no barriers with operating regions of the brain around death rate explains Gunnarsson.
The findings now available are very promising. The new series of data from the network of models will also be especially useful for researchers who are interested in finding stem cells to restore abnormal brain functions where no viable clinical options exist. We believe that our model should be of general interest to scientists and scientists interested in investigating the brain and the disease process says the scholar who been studying the progression of multiple sclerosis for 6-15 years.
Professor Gunnarsson comments: My model will have an enormous influence on the image and portrayal of the disease so that the physician and the specialist can generally agree on the information they need to decide how to treat the patient. It will also impact research related to mental diseases in which comparative models of different patients are actually used in research. My model will further the development of technologies of the brain to be distinct from the current technology.
The research team at CMU including Professor Quintus Metzner is working together for a rise in Alzheimers patients long-term treatment to help prevent further cognitive decline. The foundation is continuing to secure funding to develop a highly effective combination treatment for Alzheimers patients with lithium benzodiazepines and other drugs.
A SET-UP at the Institute for Psychiatric Research will probably be launched in April 2021. In the meantime Prof Gunnarsson will host a debate at the DUE question panel at this years DUE Congress in Geneva.
He hopes this event will be held simultaneously with the DUE Congress registration. This will further enhance the uniformity of objectives among study participants.